Menu Back toSession-2-Track-A-Other-Approaches

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 2 Track A: Clinical Experience with Immune-Targeting Oligonucleotides and MicroRNAs

Session Chair(s)

Arthur M. Krieg, MD

Arthur M. Krieg, MD

  • CEO and CSO
  • Checkmate Pharmaceuticals, United States
Daniela  Verthelyi, MD, PhD

Daniela Verthelyi, MD, PhD

  • Chief, Laboratory of Immunology, OBP, OPQ, CDER
  • FDA, United States
Therapeutic oligonucleotides offer a remarkable breadth of mechanisms and applications aside from inducing the cleavage of a target mRNA. This session explores a few of these including activating anti-tumor immunity with CpG DNA through TLR9 or with RNA and regulating the function of microRNAs.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the immune pathways that can detect foreign RNA and DNA
  • Recognize how immune activation by DNA and RNA can trigger anti-tumor immunity
  • Understand how microRNAs can be modulated to regulate cell functions


Arthur M. Krieg, MD

Overcoming Resistance to Checkpoint Inhibition with Intratumoral or Systemic Injection of a CpG-A TLR9 Agonist

Arthur M. Krieg, MD

  • CEO and CSO
  • Checkmate Pharmaceuticals, United States
Mathias  Vormehr, PhD

Antitumoral T-Cell Immunity Triggered by Systemic RNA Lipoplex Vaccination in Cancer Patients

Mathias Vormehr, PhD

  • Head of Cancer Vaccines
  • BioNTech RNA Pharmaceuticals GmbH, Germany
Diana  Escolar, MD

Clinical Development of microRNA Inhibitors

Diana Escolar, MD

  • Senior Vice President Medical Science
  • Miragen, United States